Company United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2025 BST			5-day change	1st Jan Change
300.16 ^USD	-0.13%		+1.93%	-14.93%

06-30	United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says	MT
06-30	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT

Business description: United Therapeutics Corporation

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Number of employees: 1,305

Sales by Activity: United Therapeutics Corporation

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceuticals	1.48B	1.69B	1.94B	2.33B	2.88B

See all business segments

Geographical breakdown of sales: United Therapeutics Corporation

Fiscal Period: December	2020	2021	2022	2023	2024
United States	1.41B	1.56B	1.81B	2.2B	2.74B
Rest of World	71.2M	121M	122M	125M	138M

See all geographic segments

Executive Committee: United Therapeutics Corporation

Manager	Title	Age	Since
Martine Rothblatt CEO	Chief Executive Officer	70	25/06/1996
Michael Benkowitz PSD	President	53	25/06/2016
James Edgemond DFI	Director of Finance/CFO	57	12/03/2015
Dewey Steadman IRC	Investor Relations Contact	-	31/12/2018
Paul Mahon LAW	General Counsel	61	25/06/1996

See UNITED THERAPEUTICS CORPORATION governance

Composition of the Board of Directors: United Therapeutics Corporation

Director	Title	Age	Since
Raymond Kurzweil BRD	Director/Board Member	77	31/12/2001
Martine Rothblatt CHM	Chairman	70	25/06/1996
Louis Sullivan BRD	Director/Board Member	91	31/12/2001
Raymond Dwek BRD	Director/Board Member	83	31/12/2001
Christopher Patusky BRD	Director/Board Member	61	23/10/2002
Christopher Causey BRD	Director/Board Member	62	31/12/2002
Richard Giltner BRD	Director/Board Member	61	28/04/2009
Tommy Thompson BRD	Director/Board Member	82	31/12/2009
Judy Olian BRD	Director/Board Member	73	25/06/2015
Nilda Mesa BRD	Director/Board Member	65	30/10/2018

Composition of the Board of Directors

Shareholders: United Therapeutics Corporation

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.98 %	4,929,498	10.98 %	1 416 M $
Vanguard Fiduciary Trust Co. 9.924 %	4,457,135	9.924 %	1 281 M $
Avoro Capital Advisor LLC 5.956 %	2,675,000	5.956 %	769 M $
STATE STREET CORPORATION 4.967 %	2,230,708	4.967 %	641 M $
Renaissance Technologies LLC 4.691 %	2,106,992	4.691 %	605 M $

List of UNITED THERAPEUTICS CORPORATION shareholders

Holdings: United Therapeutics Corporation

Name	Equities	%	Valuation
CELULARITY INC. 3.33%	796,885	3.33%	1,561,895 $

Company details: United Therapeutics Corporation

United Therapeutics Corp.

1000 Spring Street

20910, Silver Spring

+301 608 9292

http://www.unither.com

address United Therapeutics Corporation(UTHR)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
UNITED THERAPEUTICS CORPORATION	-0.13%	+1.93%	-8.84%	+22.93%	13.54B
ELI LILLY AND COMPANY	+0.47%	+1.46%	-15.21%	+139.25%	710B
JOHNSON & JOHNSON	+0.90%	+1.37%	+7.24%	-11.55%	379B
ABBVIE INC.	+2.30%	+2.23%	+16.04%	+27.58%	344B
NOVO NORDISK A/S	+2.82%	+3.18%	-52.84%	+14.03%	317B
ROCHE HOLDING AG	+1.15%	+1.11%	+7.52%	-18.30%	265B
NOVARTIS AG	+1.70%	+0.79%	+2.18%	+19.88%	244B
ASTRAZENECA PLC	+2.55%	+2.27%	-11.03%	-3.78%	223B
MERCK & CO., INC.	+0.37%	+1.98%	-33.34%	-9.44%	211B
AMGEN INC.	+1.30%	+0.71%	-6.62%	+20.88%	162B
Average	+1.11%	+1.43%	-9.49%	+20.15%	286.81B
Weighted average by Cap.	+1.09%	+1.11%	-9.56%	+38.09%